| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0c4322cb4de342be2dbedcbe0c278f6f |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2400-02 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6893
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-574
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57488 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 |
| filingDate |
2001-12-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dba835a80970e80fce95e5822b569f0a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_aaf7cc99a89203c6b25db4b89b03c43f |
| publicationDate |
2003-07-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-0243575-A9 |
| titleOfInvention |
Zinc alpha-2-glycoprotein as indicator of cancer |
| abstract |
The present invention relates, in general, to methods of diagnosing and monitoring cancer and inflammatory diseases/disorders and, in particular, to methods of diagnosing and monitoring cancer and inflammatory diseases/disorders that comprise assaying for elevated levels of zinc alpha-2-glycoprotein (ZAG) in serum and other body fluids. The invention also relates to methods of inhibiting thymic atrophy, including tumor-associated atrophy. |
| priorityDate |
2000-12-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |